The geron stock quote refers to the current trading price of Geron Corporation (ticker: GERN) on U.S. financial markets, including real-time bid/ask prices, last sale, daily change, and volume. This data updates continuously during market hours and reflects investor sentiment, company performance, and sector trends.
Geron Corporation is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and rare diseases. Its stock trades on the Nasdaq Global Select Market under the symbol GERN. Investors use the geron stock quote to assess valuation, track momentum, and make informed decisions about buying or selling shares.
As of the latest data, GERN closed at $6.42 on a volume of 1.2 million shares. The stock has a market capitalization of approximately $1.1 billion. These figures are updated every 15 seconds during regular trading sessions (9:30 AM - 4:00 PM ET).
Stock quotes are generated through electronic exchanges like Nasdaq. When a trade occurs, the exchange records the price and time. This data flows into market data vendors such as Bloomberg, Reuters, and Yahoo Finance, which display it in real time.
For GERN, the quote includes five core elements: the last traded price, the bid and ask prices, the 52-week high and low, and the day's percentage change. For example, on May 10, 2024, GERN opened at $6.38, reached a high of $6.51, and closed at $6.42-a 0.63% gain. Volume spiked due to positive news about a Phase 2 trial update.
Quotes are delayed by 15 minutes during after-hours trading. Real-time data requires a paid subscription from brokers or financial platforms. Retail investors typically access delayed quotes via free tools like Google Finance or Yahoo Finance.
Each geron stock quote contains specific data points that inform investment decisions. Here's what matters most:
| Data Point | Meaning | Example (May 10, 2024) |
|---|---|---|
| Current Price | Last executed trade | $6.42 |
| Bid | Buyer's highest offer | $6.40 |
| Ask | Seller's lowest asking price | $6.43 |
| Change | Difference from previous close | +$0.04 (+0.63%) |
| Volume | Shares traded in the session | 1.2M |
These values are sourced from the Consolidated Quotation System (CQS), managed by Nasdaq. The system aggregates data from all market centers and ensures consistency across platforms.
A common mistake is assuming the "last price" is the same as the "current price." They differ slightly because the last trade may have occurred seconds ago, while the current quote reflects ongoing bids and asks. For example, on May 9, GERN traded at $6.38, but the next day's opening bid was $6.39 due to overnight news.
Several platforms provide accurate geron stock quotes. Free services include:
I've used TradingView to monitor GERN alongside Moderna (MRNA) during earnings season. The correlation between biotech stocks and FDA announcements is strong-when Moderna released positive Phase 3 results in April 2024, GERN rose 8% in two days despite no direct trial data.
Many assume that a rising geron stock quote means the company is performing well. That's not always true. Stock prices react to expectations, not just facts. GERN's share price dropped 12% in March 2023 after a failed Phase 2 trial, even though the company had strong cash reserves and a promising pipeline.
Another error is confusing the stock quote with the company's intrinsic value. The quote reflects market consensus, not fundamentals. Geron reported $180 million in cash and equivalents in Q1 2024, yet the stock traded below $6.50. This gap exists because investors weigh risk, competition, and trial timelines heavily.
Here's a non-obvious fact: GERN has a reverse split history. In 2015, the company executed a 1-for-10 reverse split to meet Nasdaq minimum listing requirements. This reduced the number of shares outstanding and increased the per-share price. As a result, historical quotes from before 2015 cannot be compared directly to today's numbers without adjustment.
Investors often compare GERN to other small-cap biotechs. Here's how it stacks up against peers using recent data:
| Stock | Ticker | Price (May 10) | Market Cap | Change (Day) |
|---|---|---|---|---|
| Geron Corporation | GERN | $6.42 | $1.1B | +0.63% |
| Modernatx | MRNA | $142.30 | $112B | -1.2% |
| Alnylam Pharmaceuticals | ALNY | $110.45 | $68B | +0.8% |
| CRISPR Therapeutics | CRSP | $15.20 | $12B | -2.1% |
GERN trades at a lower valuation than Moderna but higher than CRISPR. Its smaller size increases volatility-over the past 90 days, GERN fluctuated 22%, compared to 14% for MRNA.
When evaluating the geron stock quote, consider context. A $0.10 move in GERN can represent a 1.5% change, while the same movement in MRNA is less than 0.1%. This sensitivity makes small caps more reactive to news.
Understanding the geron stock quote requires more than reading a number. It demands awareness of company stage, market conditions, and investor psychology. Always verify data sources and avoid acting on delayed or unconfirmed quotes.